Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Amortizatization of Intangibles (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Amortizatization of Intangibles for 9 consecutive years, with $931000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Amortizatization of Intangibles rose 21.54% to $931000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $3.6 million, a 203.17% increase, with the full-year FY2025 number at $3.6 million, up 203.17% from a year prior.
  • Amortizatization of Intangibles was $931000.0 for Q4 2025 at Denali Therapeutics, up from $900000.0 in the prior quarter.
  • In the past five years, Amortizatization of Intangibles ranged from a high of $11.5 million in Q2 2023 to a low of -$19.4 million in Q3 2023.
  • A 5-year average of -$230705.9 and a median of $688000.0 in 2022 define the central range for Amortizatization of Intangibles.
  • Peak YoY movement for Amortizatization of Intangibles: tumbled 5528.57% in 2021, then skyrocketed 2448.88% in 2023.
  • Denali Therapeutics' Amortizatization of Intangibles stood at -$2.4 million in 2021, then soared by 158.8% to $1.4 million in 2022, then plummeted by 1455.66% to -$19.4 million in 2023, then soared by 103.95% to $766000.0 in 2024, then grew by 21.54% to $931000.0 in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Amortizatization of Intangibles are $931000.0 (Q4 2025), $900000.0 (Q3 2025), and $898000.0 (Q2 2025).